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STRENGTHS AND LIMITATIONS OF
FUNCTIONAL HEALTH STATUS INSTRUMENTS
FOR OSTEOARTHRITIS
Kelleher JK1, Stephens JM2, Haider S3, Pashos CL1
1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Abt
Associates Clinical Trials, Bethesda, MD, USA; 3Pﬁzer, Inc,
Groton, CT, USA
The number of people with arthritis in the US was 43
million in 1998, and is projected to reach 60 million by
2020. The burden of arthritis is substantial and is respon-
sible for $65 billion annually in direct medical costs and
lost productivity. The most common form of arthritis,
osteoarthritis (OA), currently affects over 20 million
adults in the US. Because OA has no known cure, the
goals of therapy are symptom relief and improvement in
patient-reported outcomes.
OBJECTIVES: Our objective was to systematically
review disease-speciﬁc functional health status instru-
ments recommended in consensus guidelines for clinical
research in OA (as established by Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) and
OsteoArthritis Research Society International (OARSI))
and to assess their ability to predict economic outcomes.
METHODS: Computerized literature searches were 
conducted in the following databases from 1978–2002:
EMBASE, HealthSTAR, MEDLINE, and PSYCHINFO.
Manual searches were also conducted. The six disease-
speciﬁc instruments recommended by the OMERACT/
OARSI guidelines were reviewed with regard to their
domains, psychometric properties, and usefulness in 
clinical research: the Health Assessment Questionnaire,
Arthritis Impact Measurement Scales, Western Ontario
and McMaster Universities Arthritis Index, Indices of
Clinical Severity, Australian/Canadian Osteoarthritis
Hand Index, and the Algofunctional Index.
RESULTS: Substantial variation in the psychometric
properties and domains covered by the instruments was
found. Physical function and pain were the domains
which were most frequently emphasized and which
seemed to have the most value in predicting economic
burden of disease. Underrepresented areas included the
mental, social and emotional aspects of OA.
CONCLUSIONS: Additional research should evaluate
the usefulness of various instruments in assessing the
impact of OA treatments through change in physical and
psychological health status over the long term. Further
evaluation of instruments’ predictability of economic out-
comes is needed.
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CALCIUM SUPPLEMENTATION AND
REDUCTION IN ASSOCIATED FRACTURES IN
MEDICAID OSTEOPOROSIS PATIENTS
Dodd MA, Shah BM, Gupchup GV,Anderson JR
The University of New Mexico, Albuquerque, NM, USA
OBJECTIVES: To increase calcium supplementation in
Medicaid patients diagnosed with or at high risk for
osteoporosis. To reduce the number of osteoporosis 
associated bone fractures. To determine if mailing to the
patient only or the patient and their health care provider
is more effective in changing calcium prescribing.
METHODS: New Mexico Medicaid fee-for-service
patients with prescription claims for osteoporosis or
chronic oral steroid therapy without prescription claims
for calcium supplementation from October 2000 through
February 2001 were identiﬁed. The state was divided into
four geographical regions. These regions were randomly
assigned to the following intervention groups: 1) patient
only, 2) patient and prescriber, 3) patient and community
pharmacy, 4) patient, prescriber, and community phar-
macy. The patients and their health care providers were
mailed osteoporosis and calcium educational materials
according to their group. The prescription claims data-
base was reviewed 3 months following the mailing for
new calcium prescription claims. Based on a previous 
epidemiologic study and Medicare reimbursement for 
hip fractures, a cost analysis was performed.
RESULTS: A total of 1,094 patients, 239 prescribers, and
108 community pharmacies were included in the inter-
vention. Three months following the mailing 10.6% (n =
109) of the remaining eligible patients had calcium 
prescription claims. Calcium prescription claims were
present for 6.9%, 8.4%, 10.2%, and 16.6% of the
patients in groups 1, 2, 3, and 4, respectively. Hip frac-
ture associated hospital costs of $10,780 will potentially
be saved by avoiding 1.33 hip fractures per year. Net
savings of $4357 will potentially be achieved.
CONCLUSIONS: Educational materials mailed to the
patient, prescriber, and community pharmacy resulted 
in the highest change in therapy. The addition of calcium
supplementation to osteoporosis patients’ drug therapy
can potentially result in signiﬁcant cost savings and avoid
hospitalizations.
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UTILIZATION CHARACTERISTICS OF COX-2
INHIBITORS IN A LARGE MANAGED CARE
HEALTH PLAN
Yu W1, Kiang G1, Etemad LR2
1WellPoint Pharmacy Management, West Hills, CA, USA;
2University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Prevalence of COX-2 inhibitor (celecoxib
and rofecoxib) use, with or without concurrent proton
pump inhibitor (PPI) therapy, and rate of therapy switch
were determined.
METHODS: Utilizing a pharmacy claim database from a
managed care health plan of over 1.9 million commercial
members, patients who had at least one paid claim for 
a COX-2 inhibitor during the year 2000 were identiﬁed.
Rate of therapy switch was calculated as the frequency of
change in COX-2 medication during the study period.
Previous PPI users were deﬁned as patients with a PPI
claim during the 45 days prior to the initial COX-2 paid
